Summary
Danaher Corporation's first quarter 2019 filing (ending March 29, 2019) reveals a mixed performance driven by strong core sales growth offset by significant tax charges impacting net earnings. Total revenues saw a modest 4.0% increase year-over-year, with core sales growing a more robust 5.5%, indicating healthy underlying business performance across developed and high-growth markets. However, net earnings and diluted EPS experienced a notable decline compared to the prior year, primarily due to substantial discrete tax charges related to prior period uncertain tax positions and audit settlements. The company is actively pursuing strategic growth initiatives, including the pending acquisition of GE Biopharma and the planned initial public offering (IPO) of its Dental business in the second half of 2019. These significant transactions, coupled with substantial debt financing for the GE Biopharma acquisition, represent key future drivers and potential risks for the company. Investors should closely monitor the execution of these strategic moves and their impact on future financial results and leverage.
Financial Highlights
51 data points| Revenue | $4.22B |
| Cost of Revenue | $1.87B |
| Gross Profit | $2.35B |
| R&D Expenses | $267.50M |
| SG&A Expenses | $1.37B |
| Operating Income | $719.70M |
| Interest Expense | $20.50M |
| Net Income | $333.80M |
| EPS (Basic) | $0.46 |
| EPS (Diluted) | $0.46 |
| Shares Outstanding (Basic) | 707.60M |
| Shares Outstanding (Diluted) | 718.50M |
Key Highlights
- 1Total revenues grew 4.0% year-over-year, reaching $4.88 billion, while core sales (excluding acquisitions and currency impacts) increased by 5.5%, indicating solid organic growth.
- 2Net earnings significantly decreased to $334 million from $567 million in the prior year, largely due to substantial discrete tax charges of $242 million.
- 3The company is progressing with major strategic initiatives, including the planned acquisition of GE Biopharma and the anticipated IPO of its Dental business in the second half of 2019.
- 4Significant financing activities occurred, including the issuance of common and preferred stock totaling approximately $3 billion in the first quarter of 2019 to fund the GE Biopharma acquisition.
- 5Operating cash flow decreased by 15% to $703 million, attributed to lower net earnings and changes in working capital, though the company maintains a strong cash position of $3.9 billion.
- 6The Life Sciences segment showed strong growth with a 10.0% increase in total sales and 7.0% core sales growth, bolstered by acquisitions like IDT and anticipation of the GE Biopharma deal.
- 7The Diagnostics segment experienced a 1.0% total sales increase with 5.0% core sales growth, while the Dental segment saw a 2.0% decline in total sales but a 2.5% core sales increase, ahead of its planned IPO.